The successful researchers will work on the molecular mechanisms involved in control of cell growth, cancer drug resistance and will explore possible vulnerabilities of cells resistant to TOR signalling pathway inhibition, including resistant cancer cells.
Activation of mTOR promotes tumour growth and metastasis. While some of the mTOR inhibitors have been developed and approved to treat human cancer, more mTOR inhibitors are being evaluated in clinical trials. Due to the fundamental roles of mTOR in growth, cell cycle progression and anabolism within all eukaryotes, resistance to mTOR inhibition itself is a major problem, partly attributed to the large heterogeneity of cancer cells.
Results from this project will lead in a better understanding of nutrient- and growth factor-dependent cellular growth and will highlight the key candidates for targeting resistant cancer cells.
For more information visit job websites: